Modest Correlation of the New Experts with Potential New

New Post Public Reply Private Reply Replies (0) Message Board
MGK_2
726
Modest Correlation of the New Experts with Potential New Indications for CCR5 Inhibition

Dr. Paul Edison , more than likely brought on board for the indication of Alzheimer's Disease and possibly epilepsy. His work in assessing microglial activation and amyloid load showed that both these are increased in Alzheimer's disease, and microglial activation correlates with cognition, while amyloid load does not correlate with cognition. https://www.imperial.nhs.uk/consultant-directory/paul-edison



Remember, Leronlimab crosses the blood brain barrier. Microglial cells contain CCR5. Therefore LL will block the activation of microglial cells.

As in NASH, he will likely advise the employment of Brain MRI in determining Leronlimab effectiveness by measuring reduction in Alzheimer's plaques. It is now evaluating the relationship between neuroinflammation, tau, glucose metabolism, and structural and functional changes measured by MRI. He is evaluating novel microglial agents in mild cognitive impairment and Alzheimer's disease.

//



Dr. Kabir Mody , from his linked in, " I am a dedicated, practicing clinical oncologist specializing in GI oncology, in particular hepatobiliary and pancreatic malignancies. I am focused on conducting meaningful, innovative, efficient and collaborative translational and clinical research in these malignancies. He is focused on fighting these cancers specifically and would like to "leverage the immune system" to do it.

From Wiki:, "VEGF-A has been implicated with poor prognosis in breast cancer. Numerous studies show a decreased overall survival and disease-free survival in those tumors overexpressing VEGF. The overexpression of VEGF-A may be an early step in the process of metastasis, a step that is involved in the "angiogenic" switch. Although VEGF-A has been correlated with poor survival, its exact mechanism of action in the progression of tumors remains unclear. "



From here: https://www.youtube.com/watch?v=uxkc6Ql1C-U



Cancer's tend to recruit macrophages to encourage & progress tumor growth and metastasis by upregulating or overexpressing CCR5 on the surface of these "effected" macrophages. These "affected" macrophages then produce "VEGF", vascular endothelial growth factor, which in turn helps to create the blood supply to support angiogenesis and tumor growth. The "affected" macrophages promote tumor cell proliferation, endovascular migration and invasion into the blood stream where they can circulate within the body, (these become the CTC circulating tumor cells, representing degree of metastasis and degree of cancer progression) and metastasis is what kills 90% of cancer patients, not the original tumor. Normally, Natural Killer Cells should be attacking cancer cells, but because of the increased CCR5, TRegs disable the NKCs and the cancer cells are not attacked. Leronlimab interferes by blocking CCR5 preventing macrophages from exuding VEGF, preventing tumor cell proliferation, metastasis and circulating tumor cells and prevents the TRegs from disabling the Natural Killer Cells from killing tumor cells.

From here: https://breast-cancer-research.biomedcentral....21-01391-1



"Well known as an essential co-receptor for HIV, more recently, CCR5 has become strongly implicated in the progression of human cancer, in particular, metastatic cancer [13]. CCR5, a seven trans-membrane G-protein coupled receptor (GPCR), is normally expressed only in the immune system; however, CCR5 becomes overexpressed in several malignancies and is overexpressed in breast cancer [12, 13]. In the analysis of > 2200 breast cancer patients, > 50% of patient’s tumors were CCR5+. and > 95% of triple-negative breast cancer (TNBC) were CCR5+ [12]. Several characteristics of CCR5 suggest the receptor may be important in human breast cancer. CCR5 receptor levels correlate with poor prognosis in breast cancer [13,14,15]. CCR5 expression correlates well with increased tumor heterogeneity in breast cancer [16, 17]. Upon transformation of breast epithelial cells, the increased expression of CCR5 results in increased motility and homing behavior to metastatic sites [12, 13]. Furthermore, CCR5+ breast cancer epithelial cells have both enhanced tumor-initiating capacity and form mammospheres with greater efficiency in mice [13], a feature of cancer stem cells. Finally, ectopic CCR5 expression within cancer epithelial cells is sufficient to drive cancer cell metastasis [12]. "

" These studies extend prior studies by showing CCR5 inhibition both prevents metastasis and reduces the progression of established metastasis in vivo."

Remember the Basket Trial???

//



Dr. Otto Yang , from here: https://bioscience.ucla.edu/people/otto-yang/



" In particular, Dr. Yang has studied the mechanisms of HIV suppression by HIV-specific CD8+ cytotoxic T lymphocytes (CTL), which kill infected cells by recognizing viral peptides. His laboratory has demonstrated that CTL are potent killers of virus-infected cells and suppress HIV-1 replication through both killing and release of antiviral cytokines. "

From his linked in, " I am a physician-scientist who has had a basic science laboratory funded by NIH to study cellular immunology and virology for over 20 years, with over 170 peer-reviewed scientific publications in the field. Most recently my group has added SARS-CoV-2 to our research topics, and I have been the PI of 7 clinical trials of treating severe COVID-19 at UCLA Medical Center. I also remain a clinician who sees general infectious disease patients. "

https://www.youtube.com/watch?v=sCMwoVYeRA0



CytoDyn may be looking at hand and face transplants as indications as these would be indications which would require the use of Leronlimab for life as it is a variation of "Graft vs. Host" disease.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MedStar's Same-Day Test Puts Stroke Drugs on Notice

Updated Category News Views 40

A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 0

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 65

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 143

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 85

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 45

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 59

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading

Top 5 Most Recently Viewed Articles

A&K Robotics Strengthens Leadership with Melonee Wise's Expertise

Updated Category News Views 289

Leadership Expansion at A&K Robotics A&K Robotics, a frontrunner in the autonomous micromobility sector, is excited to welcome Melonee Wise to its Board of Advisors. With over twenty years of rich experience in developing robotic technologies, Wise is poised to offer invaluable insights as the company continues to grow its influence worldwide. Advancing Mobility Through...

Continue Reading
Lavior Welcomes Ryan Shilling as New VP of Sales for U.S.

Updated Category News Views 147

Lavior Welcomes Ryan Shilling as New VP of Sales for U.S. Healthcare Expertise to Drive Growth and Patient-Centered Innovation Lavior, an innovator in advanced healing solutions, proudly announces the appointment of Ryan Shilling as Vice President of Sales for the U.S. market. With over 15 years of leadership experience in various healthcare sectors, Shilling is set to...

Continue Reading
Tesla's Cybertruck Delivery Plans Set to Launch in Canada

Updated Category News Views 372

Tesla Gears Up for Cybertruck Deliveries in Canada Tesla Inc. (NASDAQ: TSLA) is approaching an exciting milestone as it plans to start delivering its much-anticipated Cybertruck in Canada shortly. Recent updates on social media suggest that the event could happen as early as next week, thrilling prospective owners. Exciting Customer Announcements On social media platform...

Continue Reading
Borregaard ASA Announces Ex-Dividend Trading Notification

Updated Category News Views 191

Borregaard ASA Ex-Dividend Trading Insights Today marks the beginning of a new trading phase for Borregaard ASA as its shares are now officially traded ex-dividend at NOK 4.25 per share. This means that investors purchasing shares at this point will not receive the forthcoming dividend, which can influence buying decisions in the market. Understanding Ex-Dividend Dates...

Continue Reading
Key Legal Notice for Charter Communications' Shareholders

Updated Category News Views 189

Current Updates on Charter Communications, Inc. Charter Communications, Inc. (NASDAQ: CHTR) has been generating significant attention as it faces an ongoing class action lawsuit regarding securities fraud. This legal proceeding serves to remind shareholders of their rights and the timelines that are critical for participation. With the stakes involved, it is vital for...

Continue Reading